Capital Raising

Tampa – October 27, 2026 -- Akari Therapeutics (Nasdaq: AKTX) reported a second-quarter 2026 net loss of $4.8 million, up from $1.9 million a year earlier, as research and development spending tripled to $2.1 million ahead of a planned Phase 1 start for its lead antibody drug conjugate (ADC), AKTX-101, in mid-2027.

Akari raised $8.6 million gross in the quarter, lifting cash to $7.7 million

The company closed a private placement with $5.5 million in gross proceeds and booked $3.1 million in gross proceeds from warrant exercises. Total gross financing was approximately $8.6 million, with approximately $8.0 million in net proceeds. Cash stood at $7.7 million on June 30, 2026, up from $5.2 million at December 31, 2025. Akari said long-term strategic investors led the financing.

PONTE VEDRA – – October 27, 2026 -- Cadrenal Therapeutics (Nasdaq: CVKD) has agreed to raise $3 million in gross proceeds from a single healthcare-focused institutional investor. Warrants could bring in about $5.8 million more if exercised in full for cash.

Cadrenal prices 960,000 shares at $3.125 with two warrant series attached

The private placement covers 960,000 common shares, or pre-funded warrants in lieu, at a combined price of $3.125 per share with accompanying warrants. The deal is priced at-the-market under Nasdaq rules. Each unit carries series C-1 and series C-2 warrants, each series covering up to 960,000 shares at a $3.00 exercise price. H.C. Wainwright & Co. is exclusive placement agent. Closing is expected on or about July 1, 2026, subject to customary conditions.

Dallas – October 15, 2026 -- Hi-TECH Beauty Labs, Corp. (HTBL) is pursuing a $5 million SEED round after the U.S. patent office issued Patent No. 12,642,834 B2 for B3 Technology®, a botanical platform for problem skin that avoids benzoyl peroxide, salicylic acid, adapalene and retinol.

The patent was issued October 15, 2026. HTBL will present its commercialization strategy and capital opportunity at the Global Capital Network Investor Conference on October 15, 2026, at the Renaissance Newport Beach Hotel in Newport Beach, California.

Patent covers three botanical ingredients

The patent protects B3 Technology®, which incorporates Black Willow Bark (Salix nigra), Cat's Claw (Uncaria tomentosa) and Dragon's Blood (Croton lechleri). HTBL describes the formulation as 100% natural and positions it as an alternative to acid-based formulations for problem skin and aging skin.

Toronto – October 12, 2026 -- Highlander Silver Corp. (TSX: HSLV) has secured a US$40 million non-brokered private placement from strategic investor Eric Sprott, who agreed to buy 8,060,226 common shares at C$6.80 each.

Sprott is described as an arm's length investor and is already a strategic shareholder of the company. The shares carry a statutory four-month hold period under Canadian securities laws.

Highlander expects US$100 million in cash after closing the Bear Creek combination

President and CEO Daniel Earle said the added capital will accelerate growth plans across the portfolio. With the investment, the company expects to hold US$100 million in cash at the closing of its previously announced combination with Bear Creek Mining, disclosed on December 19, 2025.

The combination would add the Corani silver project, which Earle described as one of the largest permitted primary silver deposits in the world.

Toronto – October 12, 2026 -- Highlander Silver Corp. (TSX: HSLV) has closed a non-brokered private placement with investor Eric Sprott, raising aggregate gross proceeds of US$40 million through the issuance of 8,060,226 common shares.

The shares were priced at C$6.80 each. The source states the proceeds in U.S. dollars and the share price in Canadian dollars.

Highlander Silver earmarks proceeds for mineral project advancement

The company plans to use the net proceeds to advance its mineral projects and for working capital and general corporate purposes. It gave no allocation by project or budget line.

Highlander Silver is primarily focused on the San Luis gold-silver project in Central Peru, adjacent to the past-producing Pierina mine.

Columbus – October 12, 2026 -- American Electric Power (Nasdaq: AEP) has launched a registered underwritten offering of $2.6 billion of common stock, structured around forward sale agreements with three banks.

BofA, Goldman Sachs and Morgan Stanley lead the underwriting

BofA Securities, Goldman Sachs & Co. LLC and Morgan Stanley are acting as joint book-running managers. Subject to certain conditions, the forward counterparties or their affiliates are expected to borrow all shares from third parties and sell them to the underwriters.

Houston – September 25, 2026 -- Nauticus Robotics (NASDAQ: KITT) has entered into a non-binding letter of intent with a strategic investor for a private placement equity investment of up to $50 million.

Strategic investor eyes up to $50 million stake in Nauticus Robotics

The autonomous subsea robotics developer disclosed the LOI on Sept. 25, 2026, framing the potential capital injection as support for its short- and long-term commercial objectives. The deal remains non-binding and does not obligate the investor to fund the transaction.

Board weighs fiduciary duties as deal terms remain unsettled

Nauticus' Board of Directors is evaluating the proposed transaction and is considering engaging an independent financial advisor to assist in its review. The investment is subject to due diligence, negotiation of definitive agreements, regulatory approvals, and closing conditions.

Vancouver – September 25, 2026 -- IM Cannabis Corp. (Nasdaq: IMCC) has closed a registered direct offering, selling 655,000 common shares at US$2.00 apiece for gross proceeds of US$1.31 million before expenses.

Las Vegas – September 25, 2026 -- Global Fight League (OTC: GFLE) has signed a seven-figure binding Letter of Intent with investor Ryan Brockbank for the rights to own and operate the league's first independently owned franchise, marking its inaugural third-party ownership deal.

GFL secures non-refundable payment to fund Argentina proof-of-concept event

GFL has received and deposited a non-refundable initial payment toward the seven-figure purchase price, with the remaining balance due in 2027. The capital will help finance an international proof-of-concept event in Argentina during the fourth quarter of 2026, with further details expected in the coming week, as well as preparations for the league's first full season of competition in 2027.

Jupiter, Florida – September 15, 2026 -- Cytonics Corporation has closed a financing campaign generating $4.8 million in gross proceeds, pushing its total capital raised to $47 million and expanding its investor base to approximately 8,000 shareholders.

Cytonics attracts 900 new investors as 35% of existing shareholders reinvest

The clinical-stage biotechnology company completed approximately 1,500 individual investments in the round, including roughly 900 first-time backers. Of the pre-raise shareholder base, 35% chose to invest again, according to the company. The raise brings cumulative funds secured through Regulation A and Regulation Crowdfunding offerings to $27 million.